Partner Content Partner Content Peripheral Interventions Market will achieve 8.7% CAGR up to... Peripheral Intervention Industry to hit $10.5bn by 2025
News ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
